铁螯合剂的应用进展：第53届美国血液学会年会报道  

Progress in iron chelators： the report of the 53rd annual meeting of American Society of Hematology

作　　者：胡晓静[1] 侯军[1] 施菊妹[1] 

机构地区：[1]上海市第十人民医院同济大学附属第十人民医院血液科,200072

出　　处：《白血病．淋巴瘤》2012年第2期73-76,共4页Journal of Leukemia & Lymphoma

摘　　要：铁螯合治疗可去除长期输血造成的铁负荷。目前全球有3种可用的螯合剂，即去铁胺、去铁酮和地拉罗司，这些螯合剂可用于单药治疗或联合治疗。在制定最佳、个体化螯合治疗方案时应考虑几个因素，包括螯合剂的可用性和特性、器官特异性的铁负荷程度、输血带来的铁负荷水平以及患者的依从性。疗效比较研究有助于制定理想的治疗方案。本文介绍2011年第53届美国血液学会（ASH）年会关于铁螯合剂应用的研究进展。Chelation therapy could remove transfusional iron burden. Three chelators are currently available, including deferoxamine, deferiprone, and deferasirox, which can be used as monotherapy or in combination. Several factors must be considered in the design of optimal and individualized chelation regimens, which include chelator availability and its properties, degree of organ-specific iron loading, ongoing transfusional iron burden, and patient preference. Comparative effectiveness trims may help to determine the ideal strategy. This article reviews latest research presented at the 53rd annual meeting of the American Society of Hematology （ASH） on the use of iron chelators.

关 键 词：铁螯合剂 血液病 美国血液学会年会 

分 类 号：R-2[医药卫生]